Locate Bio, a Nottingham, England, UK-based orthobiologics focused regenerative medicine company, raised £10m in equity funding.
The round, which brings the total funds raised by Locate Bio to over £18m, was co-led by existing shareholder Mercia Asset Management and new investor BGF.
The company intends to use the funds to further advance its proprietary pipeline of regenerative orthobiologics products towards patients, with key clinical and regulatory milestones expected to catalyze growth over the next two years.
Led by John von Benecke, CEO, Locate Bio is an orthobiologics company with a proprietary, regenerative medicine pipeline of orthobiologics products. Its portfolio includes:
- CertOss, a family of synthetic graft substitutes;
- CognitOss, a controlled and responsive release of antibiotics from a resorbable bone graft for the treatment of osteomyelitis;
- LDGraft a low dose, controlled release rhBMP-2 spinal fusion product intended for the treatment of lower back pain caused by degenerative disc disease; and
- Chondro3, a three-layer biomimetic cartilage repair graft.
Locate Bio is a spin-out from the University of Nottingham.